Merck & Co to buy $1bn stake in Seattle Genetics
16-09-2020
Merck KGaA wins injunction after MSD trademark suit
21-05-2020
Sanofi under fire over priority US access to COVID-19 vaccine
15-05-2020
Katherine Welles / Shutterstock.com
Merck Sharp & Dohme (MSD) is pushing forward with three initiatives aimed at combating the COVID-19 pandemic, including the acquisition of vaccine company Themis Bioscience.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Merck, Merck Sharp & Dohme, COVID-19, coronavirus, vaccine, collaboration
